05.15.24 -- Assessing pDNA Purity For Cell & Gene Therapies

Patient access and manufacturing efficiency persist as barriers to widespread adoption of CGTs. An effective commercialization strategy is crucial to expand access to these life-changing therapies.

Understand why the depth of management is typically less about ensuring your trial progresses smoothly and more about hiding the CRO’s deficiencies or appeasing its own stakeholders.

Industry experts share their experiences, including why and how cellular source materials are cryopreserved and why experience across cell types and methods matters.

Nucleic acid drugs hold the potential to target diseases by harnessing the power of DNA and RNA. Explore how strategic partnerships are enabling the transformative possibilities of these drugs.

Learn the principles of commercialization readiness and guidance to address them in process development as well as the best time to implement automation and minimize commercialization risks.